False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system?
- 1 February 2003
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 41 (2), 193-6
- https://doi.org/10.1161/01.hyp.0000049882.23078.eb
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Renoprotection by ACE Inhibition or Aldosterone Blockade Is Blood Pressure–DependentHypertension, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implicationsAmerican Journal of Kidney Diseases, 2001
- Aldosterone in renal diseaseCurrent Opinion in Nephrology and Hypertension, 2001
- Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonistsKidney International, 2000
- Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablationKidney International, 2000
- Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathyThe Lancet, 1997
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyNew England Journal of Medicine, 1996
- Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney modelKidney International, 1994
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993